Design, synthesis and potential 6 Hz psychomotor seizure test activity of some novel 2-(substituted)-3-{[substituted]amino}quinazolin-4(3H)-one

European Journal of Medicinal Chemistry

Volumn 46, Issue 4, 2011, Pages 1006-1018

  Kumar, Praveen ^c   Shrivastava, Birendra ^c   Pandeya, Surendra N ^a   Stables, James P ^b  

^a Saroj Institute of Technology and Management   (India)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JAIPUR NATIONAL UNIVERSITY   (India)

Author keywords

6 Hz psychomotor seizure test activity; Computational study; Neurotoxicity; Quinazolin 4(3H) one

Indexed keywords

2 METHYL 3 [(2 OXO 1,2 DIHYDRO 3H INDOL 3 YLIDENE)AMINO]QUINAZOLIN 4(3H) ONE; 2 METHYL 3 [[(3 PHENOXYPHENYL)METHYLIDENE]AMINO]QUINAZOLIN 4(3H) ONE; 2 METHYL 3 [[[3 (4 CHLOROPHENOXY)PHENYL]METHYLIDENE]AMINO]QUINAZOLIN 4(3H) ONE; 2 METHYL 3 [[[3 (4 METHYLPHENOXY)PHENYL]METHYLIDENE]AMINO]QUINAZOLIN 4(3H) ONE; 2 METHYL 3 [[[3 (4 NITROPHENOXY)PHENYL]METHYLIDENE]AMINO]QUINAZOLIN 4(3H) ONE; 2 METHYL 3 [[[3 (NAPHTHALEN 2 YLOXY)PHENYL]METHYLIDENE]AMINO]QUINAZOLIN 4(3H) ONE; 2 PHENYL 3 [[(3 PHENOXYPHENYL)METHYLIDENE]AMINO]QUINAZOLIN 4(3H) ONE; 3 [(2 OXO 1,2 DIHYDRO 3H INDOL 3 YLIDENE)AMINO] 2 PHENYLQUINAZOLIN 4(3H) ONE; 3 [[(3 PHENOXYPHENYL)METHYLIDENE]AMINO] 2 PROPYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (1,3 BENZODIOXOL 5 YLOXY)PHENYL]METHYLIDENE]AMINO] 2 METHYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (1,3 BENZODIOXOL 5 YLOXY)PHENYL]METHYLIDENE]AMINO] 2 PHENYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 BROMOPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 METHYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 BROMOPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PHENYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 BROMOPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PROPYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 CHLORO 3 METHYLPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 METHYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 CHLORO 3 METHYLPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PHENYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 CHLORO 3 METHYLPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PROPYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 CHLOROPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PHENYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 CHLOROPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PROPYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 FLUOROPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 METHYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 FLUOROPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PHENYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 FLUOROPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PROPYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 METHYLPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PHENYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 METHYLPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PROPYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 NITROPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PHENYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (4 NITROPHENOXY)PHENYL]METHYLIDENE]AMINO] 2 PROPYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (NAPHTHALEN 2 YLOXY)PHENYL]METHYLIDENE]AMINO] 2 PHENYLQUINAZOLIN 4(3H) ONE; 3 [[[3 (NAPHTHALEN 2 YLOXY)PHENYL]METHYLIDENE]AMINO] 2 PROPYLQUINAZOLIN 4(3H) ONE; 4(3H) QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRIC SHOCK; GENETIC ALGORITHM; HYDROGEN BOND; MALE; MOLECULAR DOCKING; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHARMACOPHORE; RAT; ROTAROD TEST; SEIZURE; SEIZURE THRESHOLD; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; ANIMALS; ANTICONVULSANTS; DRUG DESIGN; EPILEPSY, COMPLEX PARTIAL; GENETICS; HUMANS; HYDROGEN BONDING; LIGANDS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NERVOUS SYSTEM; QUINAZOLINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952283259     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.01.009     Document Type: Article

References (18)

1. A.V.K. Srivastava, and A. Kumar Eur. J. Med. Chem. 37 2002 873 882
2. C.B. Chapleo, M. Mayer, P.L. Myer, J.F. Saville, A.C.B. Smith, M.R. Stilling, I.F. Tulloch, D.S. Walter, and A.P. Welbourn J. Med. Chem. 29 1986 2273 2280
3. A.V.K. Srivastava, and A. Kumar Bioorg. Med. Chem. 12 2004 1257 1264
4. M.A. Aziza, M.K. Ibrahim, and A.G. El-Helpy Al-Azhar J. Pharm. Sci. 14 1994 193 201
5. A.A. Bekhit, and M.A. Khalil Pharmazie 53 1998 539
6. N. Ergenc, S. Buyuktimkin, G. Capan, G. Baktir, and S. Rollas Pharmazie 46 1991 290 291
7. S.K. Kashaw, V. Kashaw, P. Mishra, and N.K. Jain ARKIVOC xiv 2008 17 26
8. Y. Wang, S. Cai, N. Lan, J. Keana, V. Ilyin, E. Weber, PCT/US98/08004 (1998) 1-81.
9. K.H. Boltze, H.D. Dell, H. Lehwald, D. Loranz, and M. Ruberg-Schweer Arzneim-Forsch./Drug Res. 13 1963 688
10. J.F. Wolfe, T.L. Rathman, M.C. Sleevi, J.A. Campbell, and T.D. Greenwood J. Med. Chem. 33 1990 161
11. K. Unverferth, J. Engel, N. Hofgen, A. Rostock, R. Gunther, H.J. Lankau, M. Menzer, A. Rolfs, J. Liebscher, B. Muller, and H.J. Hofmann J. Med. Chem. 41 1998 63 73
12. P. Ertl, B. Rohde, and P. Selzer J. Med. Chem. 43 2000 3714 3717
13. P. Yogeeswari, D. Sriram, R. Thirumurugan, J.V. Raghavendran, K. Sudhan, R.K. Pavana, and J.P. Stables J. Med. Chem. 48 2005 6202 6211
14. C.A. Lipinski, L. Lombardo, B.W. Dominy, and P.J. Feeney Adv. Drug Deliv. Rev. 46 2001 3 26
15. Molinspiration Cheminformatics, Bratislava, Slovak Republic, Available from: http://www.molinspiration.com/services/properties.html, (accessed 16.09.10).
16. Y. Zhao, M.H. Abraham, J. Lee, A. Hersey, N.C. Luscombe, G. Beck, B. Sherborne, and I. Cooper Pharm. Res. 19 2002 1446 1457
17. V.A. Farrar, M.R. Ciechanowicz, J. Grochowski, P. Serda, T. Pilati, G. Filippini, C.N. Hinko, A. El-Assadi, J.A. Moore, I.O. Edafiogho, C.W. Andrews, M. Cory, J.M. Nicholson, and J.R. Scott J. Med. Chem. 36 1993 3517 3525
18. C.J. Landmark Med. Sci. Monit. 13 2007 RA1 7